<DOC>
	<DOCNO>NCT01259323</DOCNO>
	<brief_summary>The purpose study assess Safety Tolerability REGN668 ( body react drug ) compare placebo ( inert substance ) patient moderate-to-severe extrinsic Atopic Dermatitis .</brief_summary>
	<brief_title>Sequential Ascending Dose Study Assess Safety Tolerability REGN668 ( SAR231893 ) Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Clinical diagnosis atopic dermatitis present least 3 year screen visit Investigator 's Global Assessment ( IGA ) score &gt; /= 3 screen baseline visit &gt; /= 15 % body surface area ( BSA ) AD involvement screen baseline visit History inadequate response stable ( &gt; /= 1 month ) regimen topical corticosteroid calcineurin inhibitor treatment AD within 3 month screen visit Willing able comply clinic visit studyrelated procedure Patient able read understand , willing sign inform consent form A positive QuantiFERONÂ® TB ( tuberculosis ) Gold Test screen visit Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C and/or positive Hepatitis B surface antigen ( HBsAg ) , positive Hepatitis C antibody ( HCV ) Treatment investigational drug within 8 week baseline visit Treatment leukotriene inhibitor within 4 week baseline visit Treatment systemic corticosteroid within 4 week baseline visit Treatment topical corticosteroid , tacrolimus , and/or pimecrolimus within 1 week baseline visit Systemic treatment AD immunosuppressive/immunomodulating substance within 4 week baseline visit Chronic acute infection require treatment History clinical parasite infection , treated trichomoniasis History malignancy within 5 year baseline visit Any medical psychiatric condition , opinion investigator sponsor 's medical monitor , would place patient risk , interfere participation study , interfere interpretation study result Pregnant breastfeed woman Unwilling use adequate birth control , reproductive potential sexually active</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>